

GLAXOSMITHKLINE PLC  
Form 6-K  
April 16, 2010

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending April 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of an increase in interests in Ordinary shares purchased at a price of £12.79 per share on 15 April 2010 in GlaxoSmithKline plc, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 8 April 2010.

**Ordinary shares**

Mr A P Witty	3.27
Mr J S Heslop	0.01
Dr M M Slaoui	174.15
Mrs C E Bruck Slaoui	35.72
Mr S M Bicknell	93.45
Mr J M Clarke	182.97
Mr M Dunoyer	113.28
Mr E J Gray	199.91
Mr D S Redfern	86.73
Ms C Thomas	65.88
Mr J R Stéphenne	572.40

The Company was advised of this information on 16 April 2010.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Deputy Company Secretary

16 April 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: April 16 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc